Furthermore, in the MRL-lpr lupus model, transfer of syngeneic anti-CD19 CAR-T cells resulted in a more sustained B-cell depletion effect than antibody treatment, prevented disease pathogenesis before the onset of symptoms, and exhibited therapeutic benefits at later stages of disease progression (64). The gene discussed is CD19; the disease is systemic lupus erythematosus.